AstraZeneca/MedImmune Synergies An Advantage In Immune-Mediated Cancer Therapies

AstraZeneca’s ability to combine its small molecules with MedImmune’s biologics gives the company an edge in the burgeoning field of immune-mediated cancer therapies, MedImmune’s oncology iMed chief said in Washington, D.C. April 7 at the AACR annual meeting.